Chagas disease in bone marrow transplantation: an approach to preemptive therapy

TitleChagas disease in bone marrow transplantation: an approach to preemptive therapy
Publication TypeJournal Article
Year of Publication2005
AuthorsAltclas J, Sinagra A, Dictar M, Luna C, Veron MT, De Rissio AM, Garcia MM, Salgueira C, Riarte A
JournalBone marrow transplantation
Pagination123 - 129
Date PublishedJul
ISSN0268-3369; 0268-3369
Accession NumberPMID: 15908978; 1705006 [pii]
KeywordsAdolescent, Adult, Aged, Bone Marrow Transplantation, Chagas Disease / diagnosis / etiology / prevention & control, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Middle Aged, Nitroimidazoles / administration & dosage, Parasitemia / diagnosis / etiology / prevention & control, Retrospective Studies, Trypanocidal Agents / administration & dosage

The efficacy of preemptive therapy was evaluated in bone marrow transplantation (BMT) recipients associated with Chagas disease (CD). The criterion to include patients in the protocol was the serological reactivity for CD in recipients and/or donors before transplant. After BMT, the monitoring was performed using the direct Strout method (SM), which detects clinical levels of Trypanosome cruzi parasitemia, and CD conventional serological tests. Monitoring took place during 60 days in ABMT and throughout the immunosuppressive period in allogeneic BMT. Reactivation of CD was diagnosed by detecting T. cruzi parasites in blood or tissues. In primary T. cruzi infection, an additional diagnostic criterion was the serological conversion. A total of 25 CD-BMT patients were included. Two ABMT and four allogeneic BMT recipients showed CD recurrences diagnosed by SM. One patient also showed skin lesions with T. cruzi amastigotes. Benznidazole treatment (Roche Lab), an antiparasitic drug, was prescribed at a dose of 5 mg/kg/day during 4-8 weeks with recovery of patients. Primary T. cruzi infection was not observed. This report proves the relevance of monitoring CD in BMT patients and demonstrates that preemptive therapy was able to abrogate the development of clinical and systemic disease.

Alternate JournalBone Marrow Transplant.
Notify Library Reference ID1695

Related Incidents